mortality/aging
• increased survival relative to Rb1tm1Tyj heterozygotes, 11.6 months on a 129 background and up to 12.6 months on a mixed background
|
neoplasm
• develop grossly detectable pituitary tumors
|
• fewer thyroid C-cell adenomas than in Rb1tm1Tyj heterozygotes
|
endocrine/exocrine glands
• fewer thyroid C-cell adenomas than in Rb1tm1Tyj heterozygotes
|